On Monday, Shares of Bristol-Myers Squibb Company (NYSE:BMY), gained 2.91% to $66.48.
Bristol-Myers Squibb Company, declared that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab)+Yervoy (ipilimumab) regimen in patients with formerly untreated advanced melanoma. The FDA also granted Priority Review for this application. The projected FDA action date is September 30, 2015. This is the first regulatory milestone for an Immuno-Oncology regimen in cancer.
This new sBLA accepted by the FDA comprises data from CheckMate -069, the first randomized trial evaluating the Opdivo+Yervoy regimen in patients with formerly untreated advanced melanoma. In the trial, patients with BRAF wild-type mutation status treated with the regimen practiced improved objective response rate as contrast to patients administered Yervoy monotherapy. The Opdivo+Yervoy regimen achieved an objective response rate of 61%, counting a 22% complete response rate, in formerly untreated advanced melanoma patients. The safety profile also was consistent with formerly-stated studies evaluating the Opdivo+Yervoy regimen.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), declined -2.83% to $8.92, during its last trading session.
ARIAD Pharmaceuticals, declared updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113), in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The current results comprise more mature efficacy data for brigatinib, counting updated response rates and median duration of response in ALK+ NSCLC patients, in addition to more extensive safety data for all patients in the trial.
The updated Phase 1/2 results were presented this morning at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
At the end of Monday’s trade, Shares of Lowe’s Companies Inc. (NYSE:LOW), gained 0.23% to $70.14.
Lowe’s Canada and the Baeumler Family Foundation (BFF) are partnering to provide essential home renovations to make homes safe and accessible for those in need through a new point of sale fundraising campaign. The campaign in support of BFF is taking place in all 38 Lowe’s stores in Canada throughout the month of June 2015 where customers are invited to donate $2 at checkout.
Lowe’s has supported BFF in the past with product donations on various accessibility projects in Ontario cities counting Windsor , Markham , Burlington and Mississauga , however, this is the first year that Lowe’s is partnering with BFF for such a campaign where they are inviting customers to donate to the cause. All proceeds raised through the fundraiser will go towards BFF builds and renovation projects for underprivileged children and families in need of accessibility, safety and security in the home.
Lowe’s Companies, Inc. operates as a home improvement retailer. The company offers products for maintenance, repair, remodeling, and home decorating. It provides home improvement products under the categories of kitchens and appliances; lumber and building materials; tools and hardware; fashion fixtures; rough plumbing and electrical; lawn and garden; seasonal living; paint; home fashions; storage and cleaning; flooring; millwork; and outdoor power equipment.
Finally, Dish Network Corp. (NASDAQ:DISH), ended its last trade with 1.81% gain, and closed at $72.07.
On May 11, Dish Network, stated revenue totaling $3.7 billion for the quarter ending March 31, 2015, contrast to $3.6 billion for the corresponding period in 2014.
Net income attributable to DISH Network totaled $351 million for the quarter ending March 31, 2015, contrast to $176 million from the year-ago quarter.
DISH activated about 554,000 gross new Pay-TV subscribers contrast to about 639,000 gross new Pay-TV subscribers in the preceding year’s first quarter. Net Pay-TV subscribers declined by about 134,000 in the first quarter. The company closed the first quarter with 13.844 million Pay-TV subscribers, contrast to 14.097 million Pay-TV subscribers at the end of first quarter 2014.
Pay-TV ARPU for the first quarter totaled $86.01, contrast to first quarter 2014 Pay-TV ARPU of $82.36. Pay-TV subscriber churn rate was 1.65 percent as compared to 1.42 percent for first quarter 2014.
DISH added about 14,000 net broadband subscribers in the first quarter, bringing its broadband subscriber base to about 591,000. DISH added about 53,000 net broadband subscribers in the first quarter 2014.
DISH Network Corporation, through its auxiliaries, provides pay TV services in the United States. The company operates through two segments, DISH and Wireless. The company provides video services under the DISH brand.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.